Completed OBSERVATIONAL NCT01813721

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.

Sponsor: Amgen

Conditions Chemotherapy-induced Febrile Neutropenia

Updated 8 times since 2017 Last updated: Feb 7, 2017 Started: Dec 31, 2012 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01813721, this observational or N/A phase trial focuses on Chemotherapy-induced Febrile Neutropenia and remains completed. Sponsored by Amgen, it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
May 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — May 2017 [monthly]

Completed NA

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alès Cédex, France , Arras, France , Athens, Greece , Barcelona, Spain , Bendigo, Australia , Berlin, Germany , Besançon, France , Bialystok, Poland , Bonn, Germany , Brasov, Romania and 69 more locations